These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1728 related articles for article (PubMed ID: 12114443)
1. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Long BJ; Jelovac D; Thiantanawat A; Brodie AM Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443 [TBL] [Abstract][Full Text] [Related]
2. The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens. Brodie AH; Jelovac D; Long B J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):283-8. PubMed ID: 14623522 [TBL] [Abstract][Full Text] [Related]
3. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Lu Q; Liu Y; Long BJ; Grigoryev D; Gimbel M; Brodie A Breast Cancer Res Treat; 1999 Sep; 57(2):183-92. PubMed ID: 10598045 [TBL] [Abstract][Full Text] [Related]
5. Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens. Brodie A; Jelovac D; Long BJ Clin Cancer Res; 2003 Jan; 9(1 Pt 2):455S-9S. PubMed ID: 12538500 [TBL] [Abstract][Full Text] [Related]
6. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Sabnis GJ; Jelovac D; Long B; Brodie A Cancer Res; 2005 May; 65(9):3903-10. PubMed ID: 15867390 [TBL] [Abstract][Full Text] [Related]
7. Aromatase and breast cancer. Brodie A; Sabnis G; Jelovac D J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978 [TBL] [Abstract][Full Text] [Related]
8. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens. Sabnis G; Goloubeva O; Jelovac D; Schayowitz A; Brodie A Clin Cancer Res; 2007 May; 13(9):2751-7. PubMed ID: 17473209 [TBL] [Abstract][Full Text] [Related]
10. Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer. Núñez NP; Jelovac D; Macedo L; Berrigan D; Perkins SN; Hursting SD; Barrett JC; Brodie A Clin Cancer Res; 2004 Aug; 10(16):5375-80. PubMed ID: 15328175 [TBL] [Abstract][Full Text] [Related]
11. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Yue W; Zhou D; Chen S; Brodie A Cancer Res; 1994 Oct; 54(19):5092-5. PubMed ID: 7923123 [TBL] [Abstract][Full Text] [Related]
12. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. Brodie A; Lu Q; Liu Y; Long B; Wang JP; Yue W Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):36-40. PubMed ID: 9556790 [TBL] [Abstract][Full Text] [Related]
13. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors. McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540 [TBL] [Abstract][Full Text] [Related]
14. Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention. Sabnis G; Brodie A Clin Breast Cancer; 2010 Feb; 10(1):E6-E15. PubMed ID: 20133251 [TBL] [Abstract][Full Text] [Related]
15. Model systems: mechanisms involved in the loss of sensitivity to letrozole. Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659 [TBL] [Abstract][Full Text] [Related]
16. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen. Kijima I; Itoh T; Chen S J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. Long BJ; Jelovac D; Handratta V; Thiantanawat A; MacPherson N; Ragaz J; Goloubeva OG; Brodie AM J Natl Cancer Inst; 2004 Mar; 96(6):456-65. PubMed ID: 15026471 [TBL] [Abstract][Full Text] [Related]
18. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells. Belosay A; Brodie AM; Njar VC Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897 [TBL] [Abstract][Full Text] [Related]
20. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Ju YH; Doerge DR; Woodling KA; Hartman JA; Kwak J; Helferich WG Carcinogenesis; 2008 Nov; 29(11):2162-8. PubMed ID: 18632754 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]